Since bAb to V1/V2 were identified to correlate with decreased risk of infection in the RV144 trial, we investigated the responses induced by these vaccine regimens for their ability to recognize a panel of V1/V2-scaffold gp70 recombinant proteins containing SIVmac or SIVsm V1–V2 regions at V4wk2 (Figure 4). This evidence concerns the gene EMB and infection.